Publicaciones en colaboración con investigadores/as de University of Freiburg (12)

2021

  1. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: The SynapSES trial

    Journal of Parkinson's Disease, Vol. 11, Núm. 1, pp. 187-198

2019

  1. Author Correction: Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (Nature Genetics, (2019), 51, 3, (414-430), 10.1038/s41588-019-0358-2)

    Nature Genetics

  2. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing

    Nature Genetics, Vol. 51, Núm. 3, pp. 414-430

  3. Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: Prevalence and clinical relevance in a large international, multi-ethnic cohort of patients

    Clinical and Experimental Rheumatology, Vol. 37, pp. S97-S106

2018

  1. Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance

    Genes Chromosomes and Cancer, Vol. 57, Núm. 11, pp. 547-556

2013

  1. Monosomal karyotype in MDS: Explaining the poor prognosis

    Leukemia, Vol. 27, Núm. 10, pp. 1988-1995

2012

  1. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge

    Journal of Clinical Oncology, Vol. 30, Núm. 8, pp. 820-829

2011

  1. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease

    Nature Genetics, Vol. 43, Núm. 5, pp. 429-436

  2. Device therapy and hospital reimbursement practices across European countries: A heterogeneous scenario

    Europace, Vol. 13, Núm. SUPPL. 2

2010

  1. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study

    The Lancet Oncology, Vol. 11, Núm. 6, pp. 521-529

2007

  1. Adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebocontrolled Phase II study evaluating the MAGE-A3 cancer immunotherapeutic

    EJC SUPPLEMENTS

2006

  1. The malignant potential of a succinate dehydrogenase subunit B germline mutation

    Journal of Endocrinological Investigation, Vol. 29, Núm. 4, pp. 350-352